using Cash ~$20M, Total Debt ~$25M, MCAP ~$6M Quite cheap for a Phase-2 HIV drug with good data so far, plus AGS-003 news coming up - the big bonus IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.